Literature DB >> 31576346

Renal cell carcinoma response to checkpoint inhibitors may be predicted by senescence activity in tumor microenvironment.

Javier González1, Gaetano Ciancio2.   

Abstract

Entities:  

Year:  2019        PMID: 31576346      PMCID: PMC6685913          DOI: 10.21037/atm.2019.06.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  4 in total

Review 1.  Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma.

Authors:  Javier González; Jeffrey J Gaynor; Mahmoud Alameddine; Manuel Esteban; Gaetano Ciancio
Journal:  Expert Rev Anticancer Ther       Date:  2018-01-25       Impact factor: 4.512

2.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

3.  Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma.

Authors:  Yasmin Kamal; Chao Cheng; H Robert Frost; Christopher I Amos
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 4.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.